The Future of Hyperbaric Medicine

How Precision Dosing, Better Trials, Biomarkers, Safety Engineering, and Integrated Care May Shape the Next Era of HBOT

Hyperbaric medicine is entering a period of greater scientific scrutiny and clinical refinement. The field is moving beyond the question of whether oxygen under pressure produces measurable physiologic effects. Those effects are well established. The more important questions now concern which patients should receive treatment, what oxygen dose is appropriate, how response should be measured, and whether improvement remains meaningful after treatment ends.

The future of hyperbaric oxygen therapy, commonly abbreviated as HBOT, is unlikely to be defined by simply adding more diagnoses to treatment lists. It will depend on stronger clinical trials, more precise patient selection, standardized outcome reporting, improved safety technology, and closer integration with surgery, wound care, oncology, critical care, and rehabilitation.

HBOT will continue to have established roles in decompression sickness, arterial gas embolism, carbon monoxide poisoning, delayed radiation injury, selected diabetic foot ulcers, refractory osteomyelitis, acute traumatic ischemia, compromised grafts and flaps, and other recognized conditions. At the same time, neurologic, inflammatory, regenerative, and post-viral applications are being investigated through ongoing trials and research programs. (uhms.org)

The central challenge will be distinguishing promising investigation from premature clinical adoption.

Precision Patient Selection Will Become More Important

Many current hyperbaric indications include clinically diverse patient populations. Two patients may share the same diagnosis while having very different oxygen delivery, vascular reserve, tissue viability, inflammatory activity, and likelihood of responding to treatment.

A diabetic foot ulcer, for example, may be driven primarily by:

• Peripheral arterial disease
• Neuropathy and repetitive pressure
• Deep infection
• Osteomyelitis
• Edema
• Poor glucose regulation
• Inadequate debridement
• A combination of these factors

HBOT directly influences oxygen delivery, microbial defense, edema, and selected signaling pathways. It cannot independently correct every cause of wound failure.

Future selection models are likely to combine several types of information:

• Clinical diagnosis and disease severity
• Wound or tissue classification
• Macrovascular blood flow
• Microvascular oxygen measurements
• Imaging findings
• Laboratory and molecular biomarkers
• Response to initial standard treatment
• Comorbidities and physiologic reserve
• Patient-reported symptoms and function

This approach could reduce treatment of patients whose primary barrier is not oxygen responsive while identifying patients who may benefit before tissue injury becomes irreversible.

Precision selection will also require clinicians to define the treatment target. A patient may receive HBOT to preserve a flap, stop radiation-related bleeding, reduce tissue necrosis, support infection control, or improve neurologic recovery. Those objectives require different eligibility criteria and different definitions of success.

HBOT Will Be Treated More Explicitly as a Dose-Dependent Therapy

A hyperbaric treatment is not defined simply by entering a chamber. The delivered dose depends on several variables:

• Treatment pressure
• Inspired oxygen concentration
• Duration of oxygen exposure
• Number and length of air breaks
• Frequency of treatment
• Number of sessions
• Time between injury and treatment

Different combinations may produce different effects on oxygen delivery, edema, inflammation, angiogenic signaling, progenitor-cell mobilization, and oxygen toxicity.

Historically, many clinical protocols developed through physiology, military experience, expert consensus, and accumulated practice. Future research will increasingly compare different oxygen doses rather than treating all HBOT protocols as equivalent.

The Hyperbaric Oxygen Brain Injury Treatment Trial, or HOBIT, illustrates this shift. Its adaptive design was developed to evaluate combinations of treatment pressure and oxygen exposure in severe traumatic brain injury and identify the regimen most likely to succeed in a later definitive trial. (clinicaltrials.gov)

This type of research may help answer questions such as:

• Is 2.0 ATA sufficient for a particular chronic condition?
• Does 2.4 or 2.5 ATA improve outcomes enough to justify additional risk?
• Are two daily treatments necessary during acute tissue salvage?
• When do air breaks improve safety without reducing efficacy?
• Can some patients complete fewer sessions without losing benefit?
• Does a higher dose increase oxygen toxicity without improving the target outcome?

The future is unlikely to favor one standard protocol for every diagnosis. HBOT may develop more like pharmacology, with indication-specific dosing ranges, response-guided adjustments, and defined stopping criteria.

Biomarkers May Help Predict Treatment Response

One of the largest limitations in current practice is the difficulty of predicting response before a lengthy treatment course begins.

A useful biomarker could help identify whether the biologic pathway targeted by HBOT is active in a particular patient. Potential areas of investigation include:

• Tissue oxygen response
• Endothelial function
• Angiogenic signaling
• Inflammatory cytokines
• Oxidative stress markers
• Circulating endothelial progenitor cells
• Mitochondrial function
• Metabolic signatures
• Fibrosis-associated proteins
• Genetic or epigenetic factors

The challenge is not merely finding a laboratory value that changes after treatment. A clinically useful biomarker should predict an outcome that matters, such as wound closure, tissue salvage, reduction in bleeding, avoidance of amputation, improved cognition, or restored function.

Transcutaneous oxygen measurement already provides a practical example of response-based selection in wound care. Future methods may combine oxygen measurement with perfusion imaging, wound characteristics, and molecular data to create a more reliable probability of benefit.

Biomarkers could also identify patients at greater risk of adverse effects. Individual variation in oxygen tolerance, seizure threshold, pulmonary response, visual changes, and barotrauma remains incompletely predictable.

Imaging May Provide Better Evidence of Tissue-Level Change

Hyperbaric research frequently uses symptom scores, wound measurements, and major clinical outcomes. These remain essential, but advanced imaging may help clarify what changes within the tissue.

Potential research tools include:

• Perfusion MRI
• Functional MRI
• Diffusion imaging
• PET imaging
• Near-infrared spectroscopy
• Laser Doppler assessment
• Hyperspectral imaging
• Microvascular ultrasound
• Quantitative wound imaging

In neurologic research, imaging may help identify changes in cerebral perfusion or network activity. In wound and radiation research, imaging may document microvascular recovery, fibrosis, edema, or tissue oxygenation.

Imaging findings must be interpreted carefully. A change in blood flow or brain activation does not automatically establish improved daily function. Future trials will need to connect imaging biomarkers with patient-centered outcomes rather than treating an imaging change as proof of clinical benefit.

Better Trial Design Will Shape Which New Indications Survive

HBOT trials are difficult to design. A credible sham may require placing participants inside a chamber and changing pressure enough to preserve masking. Even modest pressure changes may create physiologic effects, making the comparison treatment imperfect.

Participants and experienced staff may also recognize differences in pressure, ear sensations, treatment duration, or oxygen-delivery equipment. This can influence expectations and reported symptoms.

The next generation of trials will increasingly use:

• Credible sham protocols
• Blinded outcome assessment
• Adaptive designs
• Multicenter enrollment
• Standardized treatment dosing
• Clearly defined patient phenotypes
• Longer follow-up
• Patient-reported outcomes
• Health-economic analysis
• Transparent adverse-event reporting

An ongoing randomized, blinded, adaptive trial is evaluating HBOT for persistent symptoms after mild to moderate traumatic brain injury in veterans and active-duty service members. Its design reflects the need for stronger masking and more rigorous neurologic outcome measurement. (clinicaltrials.gov)

Not every emerging indication will survive this level of testing. That is an essential part of scientific progress. A treatment can have a plausible mechanism and produce favorable uncontrolled case series while failing to outperform a credible comparison group.

Neurologic Applications Will Remain a Major Research Frontier

The brain is one of the most active areas of hyperbaric investigation. Researchers are studying HBOT in relation to traumatic brain injury, persistent post-concussion symptoms, stroke recovery, cognitive impairment, depression after stroke, and pediatric acquired brain injury.

Proposed mechanisms include:

• Increased oxygen availability in metabolically impaired tissue
• Changes in cerebral blood flow
• Mitochondrial support
• Angiogenic signaling
• Modulation of neuroinflammation
• Neuroplasticity
• Recruitment of surviving neural networks

These mechanisms are scientifically interesting, but neurologic symptoms are complex. Memory, fatigue, pain, sleep, mood, balance, and concentration can change because of rehabilitation, natural recovery, expectation, medication, and concurrent medical care.

A 2025 systematic review and meta-analysis found continuing interest in HBOT for neurocognitive deficits after traumatic brain injury, but the broader evidence base remains heterogeneous. Ongoing adaptive and placebo-controlled studies are intended to clarify whether specific patient groups and treatment doses produce reproducible functional benefit. (pubmed.ncbi.nlm.nih.gov)

Neurologic applications are likely to remain investigational until large, well-designed studies demonstrate durable improvements in function rather than isolated changes in imaging or symptom questionnaires.

Post-Viral and Inflammatory Conditions Will Require Cautious Evaluation

Long COVID generated substantial interest in HBOT because the condition may involve endothelial dysfunction, autonomic disturbance, inflammation, altered oxygen utilization, fatigue, and cognitive symptoms.

Early uncontrolled and small controlled studies reported improvements in selected outcomes. More rigorous research has produced a more cautious picture.

A 2025 randomized, double-blind, placebo-controlled phase 2 trial involving 10 HBOT sessions found that both the HBOT and placebo groups improved, without a significant difference in the primary short-term physical-function outcomes. (pubmed.ncbi.nlm.nih.gov)

This result does not settle every possible question about long COVID. Different symptom phenotypes, doses, treatment durations, or timing may produce different findings. It does demonstrate that improvement after treatment cannot automatically be attributed to HBOT without an appropriate comparison group.

Future research will need to define:

• Which post-viral phenotype is being treated
• Whether vascular, neurologic, autonomic, or respiratory findings predict response
• The minimum effective number of sessions
• Whether improvement persists after treatment
• How HBOT compares with rehabilitation and other treatments
• Whether the expected benefit justifies the cost and burden

Until these questions are answered, post-viral applications should remain within research or carefully governed investigational pathways.

Delayed Radiation Injury Will Continue to Drive Clinical Research

Radiation injury is likely to remain one of the strongest areas of HBOT development. Radiation can progressively damage small vessels, reduce tissue oxygenation, increase fibrosis, and impair healing years after cancer treatment.

The RICH-ART randomized trial demonstrated improvement in patient-reported urinary symptoms following HBOT for chronic radiation cystitis. Five-year follow-up published in 2025 found that clinically meaningful symptom improvement remained durable among many initial responders, although some patients required another course after recurrence. (pubmed.ncbi.nlm.nih.gov)

Future radiation research will likely focus on:

• Predicting which patients will respond
• Comparing pressure and treatment duration
• Determining the ideal number of sessions
• Identifying when retreatment is appropriate
• Measuring fibrosis and vascular recovery
• Comparing HBOT with endoscopic, pharmaceutical, and surgical alternatives
• Evaluating cost and treatment burden
• Studying organ-specific radiation injuries separately

The evidence will probably continue to become more selective. HBOT may have meaningful value for a defined radiation cystitis population while providing less benefit for another radiation-related symptom complex.

This distinction is already apparent in head and neck oncology. The 2024 ISOO-MASCC-ASCO guideline found limited evidence supporting routine HBOT for prevention or management of osteoradionecrosis, reinforcing the need to separate established historical practice from current evidence. (pubmed.ncbi.nlm.nih.gov)

Regenerative Medicine Will Focus on Mechanisms That Translate Into Outcomes

HBOT influences several processes associated with tissue repair:

• Angiogenic signaling
• Fibroblast activity
• Collagen formation
• Endothelial function
• Progenitor-cell mobilization
• Immune activity
• Redox-sensitive signaling
• Mitochondrial metabolism

These effects have encouraged interest in combining HBOT with regenerative strategies such as:

• Cellular therapies
• Tissue-engineered grafts
• Biomaterial scaffolds
• Advanced wound matrices
• Reconstructive surgery
• Orthobiologic treatments
• Rehabilitation programs

The future value of these combinations will depend on more than demonstrating that a marker increased. Researchers will need to show that combination treatment improves graft survival, bone healing, wound closure, function, or another clinically meaningful outcome beyond either treatment alone.

HBOT may eventually be used to prepare a tissue environment for another intervention or support implanted cells and engineered tissue during the period before a mature blood supply develops. These concepts remain promising but require carefully controlled translational research.

Cancer Research Will Require Precise Questions

Questions about HBOT and cancer have historically included concerns that increased oxygen availability might accelerate tumor growth or recurrence. Contemporary reviews have generally not established that appropriately prescribed HBOT promotes malignant progression, but this does not mean it should be used as a cancer treatment outside research.

The future role of HBOT in oncology is more likely to involve:

• Management of delayed radiation injury
• Support for selected reconstructive procedures
• Treatment of compromised surgical tissue
• Investigation of oxygen effects on radiation or systemic therapy
• Reduction of treatment-associated tissue damage

Any research combining HBOT with active cancer therapy must consider tumor biology, oxygen sensitivity, treatment timing, and possible interactions with chemotherapy, radiotherapy, immunotherapy, and targeted agents.

Oncologic research should remain tumor specific. Findings involving one cancer type, stage, treatment, or oxygen protocol cannot be generalized across malignancies.

Real-World Registries Will Complement Randomized Trials

Rare and emergency hyperbaric conditions are difficult to study through conventional randomized trials. Decompression illness, arterial gas embolism, severe anemia, acute traumatic ischemia, and necrotizing infections may occur too infrequently or require treatment too urgently for easy randomization.

Multicenter registries can provide valuable information about:

• Patient characteristics
• Treatment timing
• Pressure and oxygen dose
• Adverse events
• Clinical outcomes
• Treatment variation among centers
• Rare complications
• Long-term effectiveness

The UHMS Multicenter Registry for Hyperbaric Oxygen Therapy is designed to collect standardized outcome and safety information for recognized and selected emerging indications. The registry is intended to support research, quality improvement, patient care, and documentation of real-world outcomes. (uhms.org)

Registry data cannot eliminate selection bias. A patient who receives HBOT may differ from a patient who does not receive it in ways that cannot be fully measured. However, high-quality registry information can help identify treatment patterns, generate hypotheses, evaluate rare outcomes, and guide the design of future trials.

The field will benefit when participating centers use shared definitions rather than maintaining isolated internal datasets that cannot be compared.

Safety Engineering Will Become More Visible

Future progress will depend on safety as much as efficacy.

Hyperbaric treatment combines elevated pressure, high oxygen exposure, combustible materials, electrical equipment, complex medical devices, and patients who may be critically ill. Fire prevention, maintenance, product review, grounding, staff training, and emergency preparedness are fundamental clinical requirements.

In August 2025, the FDA reminded healthcare providers to follow chamber instructions for use, maintain strict fire-prevention controls, monitor patients continuously, conduct required maintenance, and control electrical or static-producing items. The communication followed reports of serious injuries and deaths associated with HBOT devices. (fda.gov)

Future chamber and facility development may include:

• More advanced oxygen monitoring
• Automated detection of environmental abnormalities
• Improved grounding and static-control systems
• Better equipment compatibility testing
• Integrated treatment verification
• More reliable gas-source identification
• Improved critical-care monitoring under pressure
• Enhanced maintenance analytics
• Standardized emergency alerts
• Better human-factor design

Automation may reduce certain errors, but it will not replace qualified staff. A system can detect an abnormal pressure or oxygen value, but trained personnel must understand its clinical meaning and respond safely.

Data Systems May Reduce Treatment Errors

Hyperbaric programs generate detailed treatment information, including pressure profiles, oxygen periods, air breaks, patient observations, glucose values, equipment checks, and adverse events.

Improved digital integration could allow:

• Automatic transfer of treatment profiles into the medical record
• Verification of the prescribed protocol against the delivered protocol
• Alerts for cumulative oxygen exposure
• Tracking of adverse-event patterns
• Identification of missed reassessment intervals
• Comparison of outcomes across indications
• Maintenance and equipment alerts
• More complete accreditation documentation

Clinical decision support might eventually identify a mismatch between a patient’s diagnosis, prescribed pressure, payer requirements, and continued-treatment criteria.

These systems must be designed carefully. Poorly configured alerts can create fatigue, while automated documentation can reproduce incorrect information at scale. Technology should support clinical judgment and safety checks rather than replace them.

Artificial Intelligence May Assist With Selection and Monitoring

Artificial intelligence could eventually combine clinical, imaging, oxygenation, wound, and laboratory data to estimate the likelihood of treatment response.

Potential applications include:

• Predicting wound-healing probability
• Identifying patients at risk of treatment failure
• Quantifying wound area and tissue characteristics from photographs
• Detecting changes in graft or flap viability
• Recognizing unusual treatment-monitoring patterns
• Forecasting missed appointments or course noncompletion
• Supporting utilization review

These applications remain early. Any predictive model would require diverse, high-quality datasets and external validation across different hospitals, chambers, patient populations, and payer environments.

An algorithm trained primarily on one type of wound or one health system may perform poorly elsewhere. Clinical teams will also need to understand which variables drive a recommendation and whether those variables reflect genuine biology or historical referral patterns.

AI should not become a method of expanding treatment volume without clinical justification.

Critical-Care Hyperbaric Medicine May Become More Regionalized

Some hyperbaric indications involve unstable patients who need mechanical ventilation, vasoactive medication, invasive monitoring, surgery, or intensive care. These include arterial gas embolism, severe carbon monoxide poisoning, necrotizing infection, acute traumatic ischemia, and exceptional blood-loss anemia.

Not every hyperbaric center can or should manage this level of acuity.

The future may involve stronger regional networks in which:

• Community hospitals identify indications early
• Hyperbaric physicians provide rapid consultation
• Transfer criteria are standardized
• Critical-care capable chambers receive complex patients
• Transport teams understand pressure-related emergencies
• Referring hospitals continue stabilization while transfer is arranged

Teleconsultation may improve early decision-making, particularly for diving emergencies, carbon monoxide poisoning, radiation complications, and potential graft or flap compromise.

Remote consultation cannot replace physical examination or chamber staffing. Its value is in helping the referring team decide whether transfer is justified and what care should continue before transport.

Workforce Development Will Be Essential

Expanding clinical capability requires trained physicians, nurses, technologists, respiratory therapists, safety leaders, and engineers.

Future workforce development will need to address:

• Formal hyperbaric education
• Chamber-specific competency
• Physician credentialing and privileging
• Critical-care training
• Emergency simulation
• Fire-safety education
• Continuing professional development
• Succession planning
• Coverage for after-hours emergencies

Programs that depend on one physician, one technologist, or one safety specialist are operationally fragile. Staff retirement, illness, or turnover can reduce capability immediately.

The future of the specialty will depend on creating durable professional pathways rather than treating hyperbaric medicine as a secondary responsibility added to an unrelated clinical role.

Accreditation and Standardization Will Become More Important

As HBOT expands into different hospital, outpatient, and private settings, variation in equipment, staffing, training, and clinical governance becomes more visible.

Accreditation provides a structure for evaluating:

• Facility safety
• Medical leadership
• Staff qualifications
• Treatment protocols
• Patient selection
• Equipment maintenance
• Emergency readiness
• Documentation
• Quality improvement
• Clinical outcomes

The UHMS accreditation program evaluates the facility as an integrated clinical system rather than assessing the chamber alone. (uhms.org)

Patients, referring clinicians, hospitals, and payers may increasingly expect evidence that a center follows recognized standards. Accreditation cannot guarantee a favorable outcome, but it can reduce reliance on informal practices and individual memory.

Economic Research Will Influence Clinical Adoption

Many HBOT courses require daily treatment over several weeks. The financial cost includes more than chamber time. Patients may face transportation, missed work, caregiving requirements, copayments, and treatment fatigue.

Hospitals must account for:

• Chamber acquisition and construction
• Oxygen and compressed-air systems
• Staffing
• Maintenance
• Fire protection
• Accreditation
• Physician supervision
• Prior authorization
• Treatment cancellations
• Compliance monitoring

Future studies will increasingly evaluate cost per meaningful clinical outcome rather than cost per chamber session.

Relevant outcomes may include:

• Amputations avoided
• Operations avoided
• Hospital admissions prevented
• Transfusions reduced
• Wound-care duration shortened
• Function restored
• Quality-adjusted life years
• Return to work
• Reduced recurrence

A treatment may be expensive per session but cost effective if it prevents a major amputation or complex reconstruction. Another treatment may improve a short-term symptom score without producing enough durable benefit to justify a lengthy course.

Economic evaluation should not be used merely to reduce access. It should help direct HBOT toward patients most likely to receive meaningful value.

Treatment Access Will Remain Uneven

Access to medical HBOT varies substantially by geography. Some regions have hospital-based programs capable of treating ventilated patients and diving emergencies. Others have outpatient wound-focused centers but no critical-care chamber. Rural or coastal areas may be many hours from recompression capability.

Improving access may require:

• Regional transfer agreements
• Shared on-call coverage
• Better emergency referral protocols
• Mobile consultation systems
• Transportation assistance
• More efficient outpatient scheduling
• Strategic placement of critical-care chambers

Increasing the number of chambers is not enough. A chamber without qualified staff, maintenance, safety infrastructure, and medical governance does not create reliable access.

Access also includes the ability to complete treatment. A patient who cannot travel five days per week may receive no practical benefit from a theoretically appropriate prescription.

Low-Pressure Wellness Services Will Remain Separate From Medical HBOT

Commercial interest in low-pressure chambers, wellness oxygen services, recovery programs, and anti-aging treatment is likely to continue.

These services should not be confused with hospital-grade HBOT delivered for a defined medical indication. Differences may include:

• Chamber pressure
• Oxygen concentration
• Device clearance
• Fire protection
• Medical supervision
• Staff competency
• Emergency capability
• Treatment objective
• Supporting evidence

A 2025 systematic review found that evidence supporting HBOT for aesthetic medicine and anti-aging remained limited and did not justify broad clinical claims. (pubmed.ncbi.nlm.nih.gov)

The future credibility of hyperbaric medicine will depend partly on maintaining this distinction. Expanding unsupported claims may create public interest in the short term, but it can weaken scientific trust, increase safety risk, and make evidence-based clinical programs harder to distinguish.

What a Future-Ready Hyperbaric Program Will Look Like

A mature hyperbaric program will not be defined primarily by the number of chambers it operates.

It will demonstrate:

• Clearly defined clinical indications
• Qualified medical and safety leadership
• Diagnosis-specific treatment protocols
• Objective response criteria
• Multidisciplinary care pathways
• Strong fire-prevention systems
• Chamber-compatible critical-care capability when offered
• Structured adverse-event review
• Participation in accreditation and registries
• Transparent clinical outcomes
• Ethical management of emerging indications
• Financial and documentation compliance

The program will also be willing to stop treatment when the objective has been reached or when evidence shows that continued exposure is unlikely to help.

This discipline is essential. A predetermined course should not continue automatically because authorization was obtained or chamber capacity is available.

The Most Important Research Priorities

Several priorities are likely to determine how the specialty develops:

1. Identifying patient phenotypes most likely to respond.
2. Comparing different pressures and oxygen doses.
3. Developing credible sham protocols.
4. Linking biomarkers and imaging to clinical outcomes.
5. Standardizing outcomes across centers.
6. Measuring durability after treatment.
7. Evaluating treatment burden and cost effectiveness.
8. Improving safety and device surveillance.
9. Building multicenter registries for rare indications.
10. Separating therapeutic evidence from promotional claims.

The next era of hyperbaric medicine will be defined less by whether HBOT can influence biology and more by whether clinicians can apply that biology predictably.

The field has compelling physiologic mechanisms, established emergency applications, and growing evidence for selected chronic tissue injuries. It also has areas where enthusiasm continues to exceed certainty.

Progress will require both openness and restraint. Researchers must remain willing to investigate new applications, while clinicians must be willing to describe those applications as investigational until credible evidence demonstrates meaningful benefit.

The future of hyperbaric medicine is therefore not unlimited expansion. It is greater precision, safer delivery, stronger evidence, and better integration with the treatments that patients already need.